| 000 | 01887 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516165315.0 | ||
| 264 | 0 | _c20140501 | |
| 008 | 201405s 0 0 eng d | ||
| 022 | _a2324-8645 | ||
| 024 | 7 |
_a10.1089/humc.2012.240 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSpanggaard, Iben | |
| 245 | 0 | 0 |
_aGene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. _h[electronic resource] |
| 260 |
_bHuman gene therapy. Clinical development _cSep 2013 |
||
| 300 |
_a99-107 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aADAM Proteins _xchemistry |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xchemistry |
| 650 | 0 | 4 | _aElectroporation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenetic Therapy _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xtherapy |
| 650 | 0 | 4 |
_aMembrane Proteins _xchemistry |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlasmids _xgenetics |
| 650 | 0 | 4 |
_aProtein Structure, Tertiary _xgenetics |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 |
_aSkin Neoplasms _xtherapy |
| 650 | 0 | 4 |
_aTransfection _xmethods |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSnoj, Marko | |
| 700 | 1 | _aCavalcanti, Andrea | |
| 700 | 1 | _aBouquet, Céline | |
| 700 | 1 | _aSersa, Gregor | |
| 700 | 1 | _aRobert, Caroline | |
| 700 | 1 | _aCemazar, Maja | |
| 700 | 1 | _aDam, Elisabeth | |
| 700 | 1 | _aVasseur, Bérangère | |
| 700 | 1 | _aAttali, Pierre | |
| 700 | 1 | _aMir, Lluis M | |
| 700 | 1 | _aGehl, Julie | |
| 773 | 0 |
_tHuman gene therapy. Clinical development _gvol. 24 _gno. 3 _gp. 99-107 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/humc.2012.240 _zAvailable from publisher's website |
| 999 |
_c23037007 _d23037007 |
||